Apellis Pharmaceuticals, Inc. (APLS)
收市後：
| 前收市價 | 43.77 |
| 開市 | 44.24 |
| 買盤 | 42.22 x 800 |
| 賣出價 | 43.00 x 800 |
| 今日波幅 | 41.58 - 44.67 |
| 52 週波幅 | 19.83 - 94.75 |
| 成交量 | |
| 平均成交量 | 4,822,920 |
| 市值 | 5.072B |
| Beta 值 (5 年，每月) | 1.07 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -5.68 |
| 業績公佈日 | 2023年11月06日 - 2023年11月10日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 67.64 |
InvestorPlace3 Very Oversold Pharma Stocks to Buy Right Now
In the financial markets, not everything always goes up, not everything always goes down. The fluctuations in the share prices of listed companies are constant. For various reasons, there are stocks with very high prices for no reason, often for the simple “animal spirit” of investors, and the same happens the other way around, good companies with excellent horizons whose shares are discounted heavily by the market. This has led to the emergence of oversold pharma stocks. There are many catalyst
InvestorPlace3 Sorry Pharma Stocks to Sell in August Before It’s Too Late
Pharmaceutical stocks can bring you from rags to riches — and back to rags again. The truth is the innovative sector can function similarly to a lottery. Not every company can deliver consistent growth and profits, but those who beat the trend will have their shares pop somewhere in the double digits in share appreciation. A few years ago, the advent of the Covid-19 pandemic saw stocks in various industries plummet. Still, pharmaceutical shares began to rise to astronomic levels due to increased
InvestorPlaceWant to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now
Biotech stocks may offer some of the most explosive opportunities on the market. For one, we have millions of baby boomers demanding better care. Two, there’s substantial demand for new innovative therapies, especially with gene editing. Three, multiple heavyweight companies are hunting for new drugs to keep their pipelines fresh with patent expirations nearing. Even better, according to The Wall Street Journal, biotech M&A is gaining big momentum. All because drug makers are facing a patent cli
